Eat dirt: CpG DNA and immunomodulation of asthma

Joel N Kline

doi:10.1513/pats.200701-019AW

Back

Eat dirt: CpG DNA and immunomodulation of asthma

Journal article

Open access

Eat dirt: CpG DNA and immunomodulation of asthma

Joel N Kline

Proceedings of the American Thoracic Society, Vol.4(3), pp.283-288

07/2007

DOI: 10.1513/pats.200701-019AW

PMCID: PMC2647631

PMID: 17607014

Files and links (1)

url

https://doi.org/10.1513/pats.200701-019AWView

Published (Version of record) Open Access

Abstract

Asthma is a disorder of increasing prevalence and severity that has been linked with reduced early-life exposure to microbes and microbial products. Populations with increased environmental exposures to pathogen-associated molecular patterns (e.g., children who have large numbers of older siblings, who were raised on farms, and who have earlier out-of-home day-care attendance) have fewer and less severe atopic disorders. The mechanism(s) responsible for these observations remain uncertain, but modulation by pathogen-associated molecular patterns of the inflammatory milieu (and thus the setting in which allergens may be encountered) has received strong support. One microbial product with marked immunostimulatory properties is bacterial DNA, which differs from mammalian DNA in the frequency of cytosine-guanine (CpG) dinucleotides; many of the effects of bacterial DNA can be recapitulated by oligodeoxynucleotides (ODNs) containing CpG in specific base sequence motifs (CpG ODNs). Because CpG ODNs induce Th1-type cytokines (which can suppress the Th2-type responses that cause many of the manifestations of allergic disease), we speculated that they may be useful in preventing or reversing the eosinophilic inflammation of atopic asthma. We found this to be the case, using murine models of incipient and established allergic asthma, but learned that the Th1-type cytokines were not critical for efficacy. Subsequent work has suggested that induction of regulatory-type responses (from T cells and antigen-presenting cells) is involved in the protection provided by CpG ODNs. Ongoing clinical trials are examining the utility of CpG ODNs alone and as an adjuvant for immunotherapy in human populations with atopic disease.

Toll-Like Receptor 9 - immunology

Adjuvants, Immunologic - pharmacology

Animals

Humans

Asthma - immunology

Immunity, Innate

Oligodeoxyribonucleotides - pharmacology

Th1 Cells - immunology

Hygiene

Toll-Like Receptor 9 - agonists

Details

Title: Subtitle: Eat dirt: CpG DNA and immunomodulation of asthma
Creators: Joel N Kline - Department of Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA. joel-kline@uiowa.edu
Resource Type: Journal article
Publication Details: Proceedings of the American Thoracic Society, Vol.4(3), pp.283-288
DOI: 10.1513/pats.200701-019AW
PMID: 17607014
PMCID: PMC2647631
NLM abbreviation: Proc Am Thorac Soc
ISSN: 1546-3222
eISSN: 1943-5665
Grant note: HL79448 / NHLBI NIH HHS HL59324 / NHLBI NIH HHS HL79447 / NHLBI NIH HHS ES05605 / NIEHS NIH HHS
Language: English
Date published: 07/2007
Academic Unit: Pulmonary, Critical Care, and Occupational Medicine; Occupational and Environmental Health; Internal Medicine
Record Identifier: 9984094602002771

Metrics

25 Record Views